H2 histamine receptor blockade in the treatment of Alzheimer disease: A randomized, double-blind, placebo-controlled trial of nizatidine

Alzheimer Disease and Associated Disorders

Volumn 16, Issue 1, 2002, Pages 24-30

  Carlson, Michelle C ^a,d   Tschanz, JoAnn T ^b   Norton, Maria C ^b   Welsh Bohmer, Kathleen ^c   Martin, Barbara K ^a   Breitner, John C S ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b UTAH STATE UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d Johns Hopkins University of Public Health ^*  (United States)

Author keywords

Alzheimer disease; Cognitive decline; Dementia; H2RAs; Histamine receptor antagonists; Nizatidine; Randomized controlled trial

Indexed keywords

AXID AR; HISTAMINE H2 RECEPTOR ANTAGONIST; NIZATIDINE; NON PRESCRIPTION DRUG; PLACEBO;

AGED; ALLELE; ALZHEIMER DISEASE; APOLIPOPROTEIN E GENE; APOLIPOPROTEIN EPSILON 4 ALLELE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; GENE; GENE LOCUS; HUMAN; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPATIAL MEMORY; TABLET; VERBAL BEHAVIOR; VERBAL MEMORY; VISUAL MEMORY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HISTAMINE H2 ANTAGONISTS; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; NIZATIDINE; NOOTROPIC AGENTS; TREATMENT FAILURE;

EID: 0036221888     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-200201000-00004     Document Type: Article

References (50)

1. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study
2. Blood levels of histamine, IL-1β and TNF-α in patients with mild to moderate Alzheimer's disease
3. Cerebrovascular changes associated with interleukin-1β (IL- 1β) and histamine (HA) levels in Alzheimer's disease. Cerebrovascular pathology in Alzheimer's disease
4. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: The Cache County study
5. Estrogen-replacement therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
6. Neuropathology of Alzheimer's disease: What is new since A. Alzheimer?
7. Inverse association of anti-inflammatory treatments and Alzheimer's disease: Initial results of a co-twin control study
8. APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: The Cache County Study
9. Delayed onset of Alzheimer's disease with nonsteroidal anti-inflammatory and histamine H2 blocking drugs
10. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration
11. Histaminergic system: Neuroendocrine function of brain histamine
12. Neuroimmune function of brain histamine: Implications for neurotrophic activity and neurotoxicity
13. Serum histamine in Alzheimer's disease and multi-infarct dementia
14. Lack of relation between race and cognitive test performance in Alzheimer's disease
15. Variability in annual Mini-Mental State Examination score in patients with probable Alzheimer's disease: A clinical perspective of data from the Consortium to Establish a Registry for Alzheimer's Disease
16. Education and other measures of socioeconomic status and risk of incident Alzheimer's disease in a defined population of older persons
17. CDP-choline-induced blood histamine changes in Alzheimer's disease
18. Global deterioration scale-related brain hemodynamics and histamine levels in Alzheimer's disease and vascular dementia. Cerebrovascular pathology in Alzheimer's disease
19. Effects of histamine and α-fluoromethylhistidine on brain tumor necrosis factor levels in rats
20. Mini-Mental State a practical method for grading the cognitive state of patients for the clinician
21. Histaminergic H2 action protects hippocampal CA1 neurons by prolonging the onset of the anoxic depolarization in gerbils
22. Estrogen replacement therapy in older women. Comparisons between Alzheimer's disease cases and nondemented control subjects
23. The pharmacological effects of ginkgo biloba, a plant extract, on the brain of dementia patients in comparison with tacrine
24. Cognitive function in nondemented older women who took estrogen after menopause
25. The Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE): Socio-demographic correlates, reliability, validity and some norms
26. Age-specific incidence rates of Alzheimer's disease. The Baltimore Longitudinal Study of Aging
27. A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease: The Baltimore Longitudinal Study of Aging
28. Histamine H2 blocking drugs and the risk for Alzheimer's disease: The Rotterdam Study
29. A placebo-controlled, double-blind, randomized controlled trial of an extract of Ginkgo biloba for dementia
30. Glutamate receptors and gene induction: Signaling from receptor to nucleus
31. Estrogen to treat Alzheimer's disease: Too little, too late? So what's a woman to do
32. Do transient ischemic attacks have a neuroprotective effect?
33. The consortium to establish a registry for Alzheimer's disease (CERAD). Part IV. Rates of cognitive change in the longitudinal assessment of probable Alzheimer's disease
34. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study
35. Cognitive involvement by negative modulation of histamine H2 receptors in passive avoidance task in mice
36. Validity of the Trail Making Test as an indicator of organic brain damage
37. Nonsteroidal anti-inflammatory drugs in Alzheimer disease
38. Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer disease
39. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study
40. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
41. Long-term increase of hippocampal excitability by histamine and cyclic AMP
42. Increased risk of mortality in Alzheimer's disease patients with more advanced educational and occupational attainment
43. Biobehavioral characteristics of nondemented older adults with subclinical brain atrophy
44. Effects of oestrogen during menopause on risk and age at onset of Alzheimer's disease
45. The modified Mini-Mental State (3MS) examination
46. Effects of estrogen on cognition, mood, and cerebral blood flow in AD. A controlled study
47. Detection and staging of dementia in Alzheimer disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer Disease